Hematopoietic stem cell transplantation (HCT) is a life-saving therapy for a variety of hematological disorders. When using allogeneic HCT as a therapy for hematological malignancies, however, the graft- versus-tumor (GVT) effect is in large part associated with graft-versus-host disease (GVHD). Therefore, controlling alloreactivity to prevent GVHD while preserving the GVT effect represents a true dilemma and the key challenge in HCT. The long-term goal of this project is to exploit the ability of foxp3-induced regulatory T cells (Tregs) to contain alloreactive T cells and to prevent GVHD while retaining the GVT effect. The central hypothesis is that forced foxp3 expression will convert a T cell clone into Tregs with a known TCR specificity, which can be activated by a specific antigen. Because the onset and duration of activation can be regulated in antigen-specific T cells, the suppressive function of these Tregs can be controlled at will. Since published data by others indicate that the GVT effect can be spared while GVHD is suppressed by Tregs, this strategy is expected to have the potential to control GVHD while preserving the GVT effect.
Three specific aims are designed to test the central hypothesis: 1) Prevent GVHD by foxp3-induced Tregs that express transgenic (Tg) TCR. CD4+CD25- cells will be isolated from WT or TCR Tg mice and converted into Tregs by foxp3-transduction via retroviral infection. The effects of WT or TCR Tg Tregs will be tested in the prevention of lethal GVHD after activation with recipient alloantigen. 2) Control GVHD by foxp3-induced Tregs that are antigen-specific cloned T cells. An antigen-specific T-cell clone will be transduced with foxp3 and used as Tregs. The effects of foxp3-expressing T cell clone will be tested in the prevention and treatment of GVHD after activation by recipient alloantigen or a peptide antigen. 3) Distinguish GVHD and the GVL effect by antigen-specific, foxp3-induced Tregs. In GVHD plus tumor models, the ability of Tregs to control GVHD while maintaining GVT effect will be compared under two conditions where Tregs are constantly activated by recipient alloantigen or transiently activated by a peptide antigen. The goal of this proposed research is to permit donor immune cells fighting against tumor, while limiting their ability to cause injury on normal tissues in the patient after bone marrow transplantation (BMT). If successful, the research would substantially enhance the therapeutic potential of BMT for the treatment of leukemia and other blood-borne diseases. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA118116-03
Application #
7477074
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Mccarthy, Susan A
Project Start
2006-08-01
Project End
2010-07-31
Budget Start
2008-08-01
Budget End
2010-07-31
Support Year
3
Fiscal Year
2008
Total Cost
$286,106
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Wu, Yongxia; Schutt, Steven; Paz, Katelyn et al. (2018) MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. Blood 131:1974-1986
Nguyen, Hung D; Kuril, Sandeepkumar; Bastian, David et al. (2018) T-Cell Metabolism in Hematopoietic Cell Transplantation. Front Immunol 9:176
Schutt, Steven D; Wu, Yongxia; Tang, Chih-Hang Anthony et al. (2018) Inhibition of the IRE-1?/XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice. Blood Adv 2:414-427
Iamsawat, Supinya; Daenthanasanmak, Anusara; Voss, Jessica Heinrichs et al. (2018) Stabilization of Foxp3 by Targeting JAK2 Enhances Efficacy of CD8 Induced Regulatory T Cells in the Prevention of Graft-versus-Host Disease. J Immunol 201:2812-2823
Heinrichs, Jessica; Bastian, David; Veerapathran, Anandharaman et al. (2016) Regulatory T-Cell Therapy for Graft-versus-host Disease. J Immunol Res Ther 1:1-14
Fu, Jianing; Wu, Yongxia; Nguyen, Hung et al. (2016) T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice. J Immunol 196:3168-79
Nguyen, Hung D; Chatterjee, Shilpak; Haarberg, Kelley M K et al. (2016) Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation. J Clin Invest 126:1337-52
Wu, Yongxia; Heinrichs, Jessica; Bastian, David et al. (2015) MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. Blood 126:1314-23
Li, Jun; Heinrichs, Jessica; Haarberg, Kelley et al. (2015) HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease. J Immunol 195:717-25
Fu, Jianing; Wang, Dapeng; Yu, Yu et al. (2015) T-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and function. J Immunol 194:388-97

Showing the most recent 10 out of 31 publications